William Blair Issues Pessimistic Forecast for NBIX Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Equities researchers at William Blair dropped their Q2 2025 earnings estimates for Neurocrine Biosciences in a research note issued on Monday, July 14th. William Blair analyst M. Minter now expects that the company will post earnings per share of $0.98 for the quarter, down from their prior forecast of $1.02. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share. William Blair also issued estimates for Neurocrine Biosciences' FY2026 earnings at $7.67 EPS.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.70 by ($0.62). The firm had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The company's revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.20 EPS.

A number of other research firms also recently commented on NBIX. Piper Sandler restated an "overweight" rating and set a $154.00 price objective (down from $160.00) on shares of Neurocrine Biosciences in a research note on Tuesday, May 6th. HC Wainwright cut their price objective on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating for the company in a report on Tuesday, April 22nd. Evercore ISI lowered their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $145.00 price target on shares of Neurocrine Biosciences in a research report on Monday, June 2nd. Finally, Guggenheim lifted their price objective on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Three research analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $163.91.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded up $1.32 during mid-day trading on Wednesday, reaching $134.80. The company's stock had a trading volume of 369,428 shares, compared to its average volume of 1,143,398. Neurocrine Biosciences has a 12 month low of $84.23 and a 12 month high of $157.98. The business's 50 day simple moving average is $125.18 and its 200 day simple moving average is $121.53. The company has a market capitalization of $13.34 billion, a price-to-earnings ratio of 45.69, a price-to-earnings-growth ratio of 1.35 and a beta of 0.24.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently modified their holdings of the company. Wolff Wiese Magana LLC boosted its stake in shares of Neurocrine Biosciences by 982.1% during the second quarter. Wolff Wiese Magana LLC now owns 844 shares of the company's stock valued at $106,000 after purchasing an additional 766 shares in the last quarter. Washington Capital Management Inc. boosted its position in Neurocrine Biosciences by 40.9% during the 2nd quarter. Washington Capital Management Inc. now owns 6,200 shares of the company's stock worth $779,000 after buying an additional 1,800 shares during the period. GAMMA Investing LLC grew its holdings in Neurocrine Biosciences by 18.9% during the 2nd quarter. GAMMA Investing LLC now owns 2,355 shares of the company's stock worth $296,000 after acquiring an additional 374 shares during the last quarter. Park Avenue Securities LLC increased its position in Neurocrine Biosciences by 14.3% in the 2nd quarter. Park Avenue Securities LLC now owns 8,094 shares of the company's stock valued at $1,017,000 after acquiring an additional 1,011 shares during the period. Finally, Atle Fund Management AB raised its stake in shares of Neurocrine Biosciences by 16.5% during the second quarter. Atle Fund Management AB now owns 88,392 shares of the company's stock valued at $11,110,000 after acquiring an additional 12,511 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Insider Buying and Selling

In other news, Director Kevin Charles Gorman sold 9,613 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total value of $1,157,212.94. Following the completion of the transaction, the director directly owned 514,596 shares in the company, valued at approximately $61,947,066.48. The trade was a 1.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Ingrid Delaet sold 457 shares of the firm's stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $135.00, for a total value of $61,695.00. Following the completion of the sale, the insider directly owned 4,730 shares in the company, valued at $638,550. This trade represents a 8.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 120,251 shares of company stock worth $14,978,602 in the last ninety days. 4.80% of the stock is owned by company insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.